JPH203 LAT1 Selectivity for Reduced Cancer-Treatment Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing anti-cancer agents targeting L-type amino acid transporter 1 (LAT1) lack specificity, leading to potential side effects on normal cells, necessitating the development of a compound with selective inhibitory activity against LAT1 for effective cancer treatment with minimal side effects.
Innovation Solution
The compound JPH203 or its pharmacologically acceptable salts are administered to patients with bile duct cancer, colorectal cancer, esophageal cancer, breast cancer, or pancreatic cancer, at doses ranging from 1 mg/m2 to 60 mg/m2, formulated as injections with pH adjusters and cyclodextrins to enhance solubility and reduce insoluble microparticles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If LAT1 inhibitors are used to treat cancer, then tumor cell proliferation is inhibited, but normal cells expressing LAT2 may also be affected causing side effects
Solution Approach 1:
The patent applies local quality by designing JPH203 with specific molecular characteristics that enable selective binding to LAT1 transporters on tumor cells while sparing LAT2 transporters on normal cells. This selectivity is achieved through the compound's unique chemical structure containing a benzoxazole core with specific substituent patterns that match the binding pocket of LAT1 but not LAT2, thereby treating cancer effectively while minimizing side effects on normal cells
Solution Approach 2:
The patent segments the population of amino acid transporters by exploiting the functional and structural differences between LAT1 (predominantly in tumor cells) and LAT2 (widely in normal cells). By developing an inhibitor that specifically targets LAT1, the treatment effectively segments its action to affect only tumor cells expressing LAT1, leaving normal cells with LAT2 unaffected
2Productivity
If high doses of LAT1 inhibitors are administered to achieve tumor shrinkage, then therapeutic effect is improved, but toxicity and side effects increase
Solution Approach 1:
The high therapeutic index of JPH203 is achieved through its selective action on LAT1-expressing tumor cells. The compound's molecular structure enables it to concentrate its inhibitory effect locally at tumor cell LAT1 transporters, achieving significant tumor shrinkage at doses that do not cause substantial toxicity to normal cells, thus resolving the contradiction between efficacy and safety
Data Source
AI summary
O-(5-amino-2-phenylbenzoxazol-7-yl)methyl-3,5-dichloro-L-tyrosine or a pharmacologically acceptable salt thereof exhibits high therapeutic effects on bile duct cancer, colorectal cancer, esophageal cancer, breast cancer, and pancreatic cancer.